AI
HAE icon

Ariel Investments’s Haemonetics HAE Stock Holding History

Ariel Investments’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155M Buy
+2,060,966
New +$132M 1.54% 29

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Ariel Investments's HAE Position: Q2 2026 in Review

Ariel Investments opened a new position in Haemonetics (HAE) in Q2 2026: 2,060,966 shares worth $155M. The stake represents 1.54% of the portfolio and ranks #29 among its holdings.

316 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Ariel Investments held 2,060,966 shares of Haemonetics worth $155M as of Q2 2026.
  • Haemonetics was a new Ariel Investments position in Q2 2026.
  • Haemonetics made up 1.54% of Ariel Investments's portfolio in Q2 2026, its #29 holding.
  • 316 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Ariel Investments's 13F filing for Q2 2026, filed 14 Aug 2026.